Vienna, Va., November 10, 2026--Cel-Sci s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research.
Why Is Cel-Sci Corporation (CVM) Stock Up Today?
Updated Nov 16, 2026 8:00 PM ET · Prev Close $1.28
Primary Move Catalyst & Conviction
65% Signal ConvictionOutperforming sector by 27.4%
This stock is significantly outperforming its Biotechnology & Biological Products sector peers, suggesting a stock-specific catalyst.
Market & Sector Relative Strength
CVM outperforming the S&P 500 by +26.11%Options Flow & Execution Desk
Recent CVM Catalyst Headlines
Verified WireCel-Sci Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company s completed Phase 3 study of Multikine Leukocyte Interleukin, Injection , an in
Vienna, Va,, October 26, 2026--Cel-Sci presents Phase 3 Multikine data at World Congress Pre-Surgical Biomarkers Identify Head Neck Cancer Patients Achieving 73 5-Year Survival.
Vienna, Va., September 15, 2026--Cel-Sci invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.
1–3 Day Expected Range & Key Level
55% Follow-ThroughWatch for continuation above $1.59
Technical Regime (CVM)
MIXED MA TREND1-Year Historical Move Analogs
61 EventsSessions in the past year where CVM moved >3.0% up:
Retail & Crowd Sentiment
BullishCel-Sci presented new Phase 3 Multikine data at the World Congress, identifying a significant increase in pre-surgical response and substantial overall survival advantage for head neck cancer patients with specific biomarkers.
About Cel-Sci Corporation
Cel-Sci Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances...
Get Instant CVM Catalyst Alerts
Receive an email alert when CVM triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCVM Session & Catalyst FAQ
Why is CVM stock up today?
This stock is significantly outperforming its Biotechnology & Biological Products sector peers, suggesting a stock-specific catalyst.
Is CVM stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 6.78x relative volume (high participation). Our multi-factor model currently rates CVM as HOLD. Review full valuation, quality, and timing signals on the CVM Buy or Sell Decision Brief →
What is CVM's intrinsic value and expected trading range?
At $1.59, CVM's modeled 1-to-3 session range is $1.56 – $1.64, with a key inflection level at $1.67 (resistance). Compare current price against multi-year cash flow projections in the CVM Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for CVM?
RSI at 57.1 reflects constructive bullish momentum. CVM trades at $1.59 relative to its 20-day SMA ($1.46) and 50-day SMA ($1.66), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.